Mark Goldstein, MD
Dermatology · New Haven, CTNPI 1902947484
Payments from drug & device makers
Across 54 payments — averaging $51.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$2K
- Pfizer$465
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$283
- Journey Medical Corporation$203
- Almirall LLC$81
- Gilead$78
- plus $110 from 7 others
What the payments were for
- Consulting fees$1,20043%
- Food & beverage$1,57457%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 8 | $1,554 |
| Pfizer | 20 | $465 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 9 | $283 |
| Journey Medical Corporation | 4 | $203 |
| Almirall LLC | 3 | $81 |
| Gilead | 3 | $78 |
| Merck | 1 | $18 |
| Sebela Pharmaceuticals Inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Taro Pharmaceuticals USA, Inc. | 1 | $15 |
| Encore Dermatology Inc. | 1 | $15 |
| Mission Pharmacal Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOOLANTRA$1,469
- EUCRISA$232
- DUOBRII$129
- EPIDUO FORTE$120
- ORACEA$120
How this compares
$2,774 in reported general payments places this provider in the 45th percentile of 222 dermatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Calcipotriene | 18 | $2,571 |
| Ketoconazole | 259 | $2,435 |
| Metronidazole | 21 | $1,308 |
| Triamcinolone Acetonide | 199 | $1,206 |
| Clindamycin Phosphate | 26 | $966 |
| Clobetasol Propionate | 38 | $861 |
| Tacrolimus | 11 | $789 |
| ErythromycinErythromycin Base In Ethanol | 20 | $739 |
| Ammonium Lactate | 71 | $685 |
| Desonide | 45 | $551 |
| Betamethasone Dipropionate | 19 | $498 |
| Mupirocin | 63 | $429 |
| Minoxidil | 35 | $279 |
| Mometasone Furoate | 38 | $269 |
| Hydrocortisone | 49 | $256 |
Paid to pharmacies, not to this prescriber.
Other dermatology in New Haven
- Lisa DonofrioNew Haven$2.3M
- Christopher BunickNew Haven$1.7M
- William DamskyNew Haven$1M
- Keith ChoateNew Haven$695K
- Michael GirardiNew Haven$424K
- Richard AntayaNew Haven$314K
- Jeff GehlhausenNew Haven$138K
- Shawn CowperNew Haven$135K
- David LeffellNew Haven$94K
- Mariam TotonchyNew Haven$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.